Validation of predictive equations for resting energy expenditure in obese adolescents

Geesje H Hofsteenge, Mai J M Chinapaw, Henriette A Delemarre-van de Waal, Peter J M Weijs, Geesje H Hofsteenge, Mai J M Chinapaw, Henriette A Delemarre-van de Waal, Peter J M Weijs

Abstract

Background: When the resting energy expenditure (REE) of overweight and obese adolescents cannot be measured by indirect calorimetry, it has to be predicted with an equation.

Objective: The aim of this study was to examine the validity of published equations for REE compared with indirect calorimetry in overweight and obese adolescents.

Design: Predictive equations based on weight, height, sex, age, fat-free mass (FFM), and fat mass were compared with measured REE. REE was measured by indirect calorimetry, and body composition was measured by dual-energy X-ray absorptiometry. The accuracy of the REE equations was evaluated on the basis of the percentage of adolescents predicted within 10% of REE measured, the mean percentage difference between predicted and measured values (bias), and the root mean squared prediction error (RMSE).

Results: Forty-three predictive equations (of which 12 were based on FFM) were included. Validation was based on 70 girls and 51 boys with a mean age of 14.5 y and a mean (+/-SD) body mass index SD score of 2.93 +/- 0.45. The percentage of adolescents with accurate predictions ranged from 74% to 12% depending on the equation used. The most accurate and precise equation for these adolescents was the Molnar equation (accurate predictions: 74%; bias: -1.2%; RMSE: 174 kcal/d). The often-used Schofield-weight equation for age 10-18 y was not accurate (accurate predictions: 50%; bias: +10.7%; RMSE: 276 kcal/d).

Conclusions: Indirect calorimetry remains the method of choice for REE in overweight and obese adolescents. However, the sex-specific Molnar REE prediction equation appears to be the most accurate for overweight and obese adolescents aged 12-18 y. This trial was registered at www.trialregister.nl with the Netherlands Trial Register as ISRCTN27626398.

Source: PubMed

3
Subskrybuj